- Current Studies Parkinson’s Disease AbbVie M12-927 INSIGHTS: A 26-week study comparing Levodopa-Carbidopa gel therapy to improve medical treatment of non-motor symptoms in people with advanced Parkinson's Disease. ACADIA ACP-103-048: A 8-week study of safety and efficacy for adjunctive pimavanserin treatment in people Parkinson’s Disease and poorly controlled depression. ACADIA ACP-NIS-001: An observational study of the management of Parkinson's Disease psychosis in actual practice (The INSYTE Study). Biogen 228PD201: A phase 2A study of the safety, pharmacokinetics, and pharmacodynamics of BIIB054 in people with Parkinson’s Disease who’ve been diagnosed for a maximum of 3 years. Dong-A DA-9805-PD-001: A phase 2A of an herbal extract to test the safety, tolerability and efficacy of DA-9805 in people with early Parkinson’s Disease to delay disease progression. NeuroDerm ND0612L-007 (iNDiGO): A study testing the efficacy, tolerability, and safety of two dosing groups of ND0612, given through pump infusions as additional treatment to oral levodopa in people with Parkinson’s Disease with motor fluctuations. NeuroDerm ND0612H-012 (BeyoND): A study of ND0612 solution of levodopa/carbidopa given with a pump system infusion in people with advanced Parkinson's Disease. Northwestern University NILO-PD: A phase 2A to test the safety, tolerability, and clinical and exploratory biological activity of treatment with nilotinib (NILO) in people with late-stage Parkinson’s Disease. Multiple Sclerosis - Current Studies Novartis CFTY720DUS40 (FLUENT): A 12-Month study in people with relapsing MS (RMS), to look at changes in immune phenotype biomarkers after treatment with 0.5 mg fingolimod (FTY720).
Parkinson’s Disease - Current Studies AbbVie M12-927 INSIGHTS: A 26-week study comparing Levodopa-Carbidopa gel therapy to improve medical treatment of non-motor symptoms in people with advanced Parkinson's Disease. ACADIA ACP-103-048: A 8-week study of safety and efficacy for adjunctive pimavanserin treatment in people Parkinson’s Disease and poorly controlled depression. ACADIA ACP-NIS-001: An observational study of the management of Parkinson's Disease psychosis in actual practice (The INSYTE Study). Biogen 228PD201: A phase 2A study of the safety, pharmacokinetics, and pharmacodynamics of BIIB054 in people with Parkinson’s Disease who’ve been diagnosed for a maximum of 3 years. Dong-A DA-9805-PD-001: A phase 2A of an herbal extract to test the safety, tolerability and efficacy of DA-9805 in people with early Parkinson’s Disease to delay disease progression. NeuroDerm ND0612L-007 (iNDiGO): A study testing the efficacy, tolerability, and safety of two dosing groups of ND0612, given through pump infusions as additional treatment to oral levodopa in people with Parkinson’s Disease with motor fluctuations. NeuroDerm ND0612H-012 (BeyoND): A study of ND0612 solution of levodopa/carbidopa given with a pump system infusion in people with advanced Parkinson's Disease. Northwestern University NILO-PD: A phase 2A to test the safety, tolerability, and clinical and exploratory biological activity of treatment with nilotinib (NILO) in people with late-stage Parkinson’s Disease. Multiple Sclerosis - Current Studies Novartis CFTY720DUS40 (FLUENT): A 12-Month study in people with relapsing MS (RMS), to look at changes in immune phenotype biomarkers after treatment with 0.5 mg fingolimod (FTY720).
tajqfpq7sfe4ddi1f9a4iinwr_january_newsletter.docx